PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia

Blood

Volumn 126, Issue 2, 2015, Pages 203-211

  McClanahan, Fabienne ^a,b   Hanna, Bola ^b   Miller, Shaun ^a   Clear, Andrew James ^a   Lichter, Peter ^b   Gribben, John G ^a   Seiffert, Martina ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN G2B; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTIBODY; CD274 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFECT; DRUG TARGETING; EX VIVO STUDY; FEMALE; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL SYNAPSE; IMMUNOPATHOLOGY; IN VIVO STUDY; LEUKEMOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CELL TRANSFORMATION; DISEASE MODEL; DRUG EFFECTS; IMMUNE SYSTEM DISEASES; IMMUNOLOGY; INFLAMMATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PATHOLOGY; PHYSIOLOGY;

ANIMALS; ANTIBODIES; ANTIGENS, CD274; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNE SYSTEM DISEASES; INFLAMMATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, INBRED C57BL;

EID: 84937780079     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-622936     Document Type: Article

References (41)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-264.
3. Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy. Blood. 2013;121(5):734-744.
4. Wherry EJ. T cell exhaustion. Nat Immunol. 2011; 12(6):492-499.
5. Burkhardt UE, Hainz U, Stevenson K, et al. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013;123(9):3756-3765.
6. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013;121(9):1612-1621.
7. Rezvany M-R, Jeddi-Tehrani M, Wigzell H, Ö sterborg A, Mellstedt H. Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia. Blood. 2003;101(3):1063-1070.
8. Riches JC, Gribben JG. Understanding the immunodeficiency in chronic lymphocytic leukemia: Potential clinical implications. Hematol Oncol Clin North Am. 2013;27(2):207-235.
9. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427-2437.
10. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: Establishing a reversible immune evasion mechanism in human cancer. Blood. 2012;120(7):1412-1421.
11. Brusa D, Serra S, Coscia M, et al. The PD-1/PDL1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica. 2013; 98(6):953-963.
12. te Raa GD, Pascutti MF, Garć?a-Vallejo JJ, et al. CMV-specific CD81 T-cell function is not impaired in chronic lymphocytic leukemia. Blood. 2014;123(5):717-724.
13. Jitschin R, Braun M, Büttner M, et al. CLL-cells induce IDOhi CD141HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood. 2014;124(5):750-760.
14. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA. 2002;99(10):6955-6960.
15. Gorgun G, Ramsay AG, Holderried TAW, et al. E(m)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA. 2009;106(15): 6250-6255.
16. Hofbauer JP, Heyder C, Denk U, et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia. 2011;25(9):1452-1458.
17. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2(5): 662-673.
18. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4): 311-319.
19. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114(8):1545-1552.
20. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010; 207(10):2187-2194.
21. Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014; 124(2):687-695.
22. Paterson AM, Brown KE, Keir ME, et al. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011;187(3):1097-1105.
23. Burger JA, Tsukada N, Burger M, Zvaifler NJ, Dell'Aquila M, Kipps TJ. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cellderived factor-1. Blood. 2000;96(8):2655-2663.
24. Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009;325(5940):612-616.
25. Maffei R, Bulgarelli J, Fiorcari S, et al. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica. 2013;98(7): 1115-1123.
26. Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):e74-e80.
27. Yrlid U, Jenkins CD, MacPherson GG. Relationships between distinct blood monocyte subsets and migrating intestinal lymph dendritic cells in vivo under steady-state conditions. J Immunol. 2006;176(7):4155-4162.
28. Arnold L, Henry A, Poron F, et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med. 2007;204(5): 1057-1069.
29. Herishanu Y, Katz B-Z, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: Clinical and therapeutic implications. Hematol Oncol Clin North Am. 2013;27(2):173-206.
30. Loke P, Allison JP. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A. 2003;100(9):5336-5341.
31. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: A potential mechanism of immune paralysis. Cancer Res. 2003;63(21):7462-7467.
32. Chen L, Zhang Z, Chen W, et al. B7-H1 upregulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol. 2007;178(10): 6634-6641.
33. Görgün G, Holderried TAW, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005;115(7): 1797-1805.
34. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562-567.
35. Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009; 114(10):2149-2158.
36. Spranger S, Koblish HK, Horton B, Scherle PA, Newton R, Gajewski TF. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(1) T cells directly within the tumor microenvironment. J Immunother Cancer. 2014;2(1):3.
37. Yu P, Steel JC, Zhang M, et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci USA. 2012; 109(16):6187-6192.
38. Wainwright DA, Chang AL, Dey M, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014; 20(20):5290-5301.
39. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity. 2013; 39(1):61-73.
40. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(10): 3044-3051.
41. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A SINGLE GROUP, OPEN-Label, phase 2 trial. Lancet Oncol. 2014; 15(1):69-77.